Patient holding a pre-filled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection. | |
Licence : | Droits gérés |
Crédit: | Science Photo Library / Marazzi, Dr. P. |
Taille de l’image : | 6048 px × 4024 px |
Model Release : | Disponible |
Restrictions : |
|